9 results match your criteria: "Andros Men's Health Institutes[Affiliation]"
Re: Maarten De Rooij, Clare Allen, Jasper J. Twilt, et al. PI-QUAL Version 2: An Update of a Standardised Scoring System for the Assessment of Image Quality of Prostate MRI. Eur Radiol. In press. https://doi.org/10.1007/s00330-024-10795-4.
Eur Urol
November 2024
Department of Radiology, Andros Men's Health Institutes BV, Arnhem, The Netherlands. Electronic address:
Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review.
Heliyon
December 2022
Andros Men's Health Institutes, Arnhem, the Netherlands.
Compared to females, males experience severe acute respiratory syndrome due to COVID-19 (SARS-CoV-2) more often, and also die more frequently from COVID-19. Testosterone has inhibitory and estrogens have favorable effects on the immune system. Both ACE2 and TMPRSS2 are specific host-cellular proteins stimulating viral entry in cells and SARS-CoV-2.
View Article and Find Full Text PDFEstetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study.
Eur Urol Open Sci
November 2022
Pantarhei Oncology, Zeist, The Netherlands.
Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is accompanied by side effects affecting health-related quality of life (HRQL).
Objective: To assess the effects of the fetal estrogen estetrol (E4) on symptoms related to estrogen and androgen deficiency, and on HRQL measured using the validated Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.
Design Setting And Participants: This was a phase 2, double-blind, randomized, placebo-controlled study in patients with advanced PCa.
Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.
Eur Urol
November 2021
Andros Men's Health Institutes, Arnhem, The Netherlands.
A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men.
J Clin Endocrinol Metab
September 2018
Andros Men's Health Institutes, CV Arnhem, Netherlands.
Context: Luteinizing hormone-releasing hormone (LHRH) agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The fetal estrogen estetrol (E4) may be safer for PC treatment and is expected to decrease testosterone (T) and prevent estrogen deficiency.
Objective: To investigate the safety and T-suppressive effect of E4 in healthy men.
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
J Sex Med
September 2017
New England Research Institutes, Inc, Watertown, MA, USA.
Article Synopsis
- - The study examined the long-term effects of testosterone replacement therapy (TRT) on quality of life (QOL) and sexual function in men with low testosterone levels, using data from a multinational registry over 36 months.
- - Results showed that men receiving TRT experienced significant improvements in QOL and sexual function, reporting fewer symptoms compared to those who did not receive treatment; TRT patients scored better on established assessment scales like the AMS and IIEF.
- - The findings suggest that TRT can lead to sustained enhancements in the life quality of men with hypogonadism, although some improvement was also noted in untreated patients, emphasizing the effectiveness of TRT over time.
Precision surgery and genitourinary cancers.
Eur J Surg Oncol
May 2017
Andros Men's Health Institutes, Arnhem, The Netherlands. Electronic address:
The landscape of the surgical management of urologic malignancies has dramatically changed over the past 20 years. On one side, better diagnostic and prognostic tools allowed better patient selection and more reliable surgical planning. On the other hand, the implementation of minimally invasive techniques and technologies, such as robot-assisted laparoscopy surgery and image-guided surgery, allowed minimizing surgical morbidity.
View Article and Find Full Text PDFObjectives: To evaluate the effects of testosterone-replacement therapy (TRT) on prostate health indicators in hypogonadal men, including rates of prostate cancer diagnoses, changes in prostate-specific antigen (PSA) levels and lower urinary tract symptoms (LUTS) over time.
Patients And Methods: The Registry of Hypogonadism in Men (RHYME) is a multi-national patient registry of treated and untreated, newly-diagnosed hypogonadal men (n = 999). Follow-up assessments were performed at 3-6, 12, 24, and 36 months.